100 results about "Montelukast" patented technology

A solid form of a compound of formula 1: is provided. The compound of formula 1 can be obtained in solid state by precipitation from a solution containing the same. The compound is useful as leukotriene antagonist and can be formulated into a pharmaceutical composition that also includes a pharmaceutically acceptable excipient.

A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: using a compound of formula (20) is provided.

The present invention relates to amorphous and polymorphic forms of montelukast free acid.

The present invention provides a process for stereoselectively reducing 2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]-phenyl]-3-oxopropyyl]benzoic-acid methyl ester, to produce to produce methyl 2-[3-(S)-[3-[2-(7-chloro-2-quinolinyl)-ethenyl]phenyl]-3-hydroxypropyl]benzoate, and a process for producing montelukast or a salt thereof. The present invention further provides a process for purifying methyl 2-[3-(S)-[3-[2-(7-chloro-2-quinolinyl)-ethenyl]phenyl]-3-hydroxypropyl]benzoate. The reduction process of the present invention uses a chiral reagent and can produce the desired reduction product in high enantiomeric excess (ee).

The manufacture of compositions containing montelukast and to stable tablet compositions resulting thereof are disclosed, which include a first compaction step of a dry blend including, montelukast or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, and a further compression step into tablets.

The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and / or modified-release elements, providing for drug delivery to the patient.

The invention discloses a method for preparing montelukast acid. The method comprises a reaction b or a reaction a to a reaction b in the following synthetic route: the formula is shown in the description. The method disclosed by the invention can be used for preparing montelukast acid and salts thereof with low cost and high yield by means of simple operations by using low-cost and easily available raw materials, and is of significance and has practical value to prepare montelukast acid and salts thereof with low cost on a large scale.

An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer.

A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: using a compound of formula (11) is provided.

Processes for preparing montelukast acid and its salts.

The reaction of methylmagnesium halide is improved by the presence of a cerium (III) salt such as cerium trichloride. The reactions are typically associated with the production of montelukast, a pharmaceutically useful compound of the following formula and salts thereof. Further enhancements can be derived from certain intermediates, salts thereof and / or purification thereof before and / or after the reaction involving methylmagnesium halide.

The invention relates to a stable Montelukast oral film preparation. The oral film preparation contains an effective amount of Montelukast or pharmaceutically acceptable salts of the Montelukast, a drug stabilizer at least comprising edetic acid and / or editate as well as pharmaceutically acceptable auxiliary materials. The Montelukast oral film preparation obtained according to the formula is accurate in dose, stable in quality and capable of effectively preventing oxidization and degradation of effective components, has the advantages of bright color, good taste, capability of being quickly dissolved in an oral cavity without water, improves the administration compliance of a patient and is particularly suitable for infants and patients suffering from dysphagia.

The invention discloses a method for preparing a montelukast nano chiral alcohol intermediate. In alkali and solvent environment, 2-[3-[3-[2-(7-chloro-2-quinolyl) vinyl] phenyl]-3-oxo propyl] methyl benzoate (II) is subjected to catalytic hydrogenation reaction by using a transition metal complex as a catalyst to generating 2-[3-(S)-[3-[2-(7-chloro-2-quinolyl)-phenyl] vinyl]-3-hydroxy propyl methyl benzoate (I), wherein the transition metal complex has a general formula of MLnL'XY, and is a nitrogen phosphine transition metal formed by coordination of a ligand with NH2-N(sp2) or NH2-NH2 structural characteristic and a transition metal complex. The preparation method has the advantages of small catalyst amount, mild reaction conditions, stable process, conversion rate of more than 98%, less pollution, and high yield and high purity of obtained product, and has the very good value of industrialization.

An improved process for the preparation of Montelukast and its pharmaceutically acceptable salts comprises of reacting (S) Benzenepropanol α-[3-[2-(7-chloro2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methyl ethyl)-α-methane sulfonate compound of formula (II) with 1-(mercapto methyl)cyclo propane acetic acid or its ester or nitrile in presence of alkali or alkaline carbonates and / or alkali or alkaline earth metal alkoxide in a suitable polar aprotic solvent with or without combination of C1-C4 alcoholic solvents and then treating with organic amine in a suitable ester and / or acetone and / or aliphatic or aromatic hydrocarbon solvents, and converting the corresponding amine salt compound of montelukast into its sodium salt compound of formula (I) using sodium ion source in methanol, without converting into montelukast free acid.

A pharmaceutical composition useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitus, allergy, asthma, allergic asthma and / or inflammation, in a mammalian organism in need of such treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from a) montelukast, b) 1-(((R)- (3-(2-(6,7- difluoro-2- quinolinyl)ethenyl) phenyl)-3-(2- (2-hydroxy-2- propyl)phenyl) thio)methylcyclopropaneacetic acid; c) 1-(((1(R)-3 (3-(2-(2,3- dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl) -3-(2-(1-hydroxy-1- methylethyl) phenyl)propyl) thio)methyl) cyclopropaneacetic acid; d) pranlukast; or f) [2-[[2-(4-tert -butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixture with ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.

The invention relates to a pharmaceutical composition for treating asthma, allergic reaction and inflammation. The composition comprises a leukotriene antagonist, antihistaminics and medicinal carriers, wherein the leukotriene antagonist is Montelukast and salts thereof, and the antihistaminics is olopatadine hydrochloride and salts thereof. The composition is suitable for preventing and long-term treating of asthma for children and adults, and can treat asthma patients sensitive to aspirin, prevent bronchoconstriction induced by movement, treat pruritus concomitant with allergic rhinitis, urticaria and skin diseases, and the like. The composition has better curative effect compared with that the two medicines are used independently.

A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof:using a compound of formula (11)is provided.

A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

The invention belongs to the technical field of medicine, and in particular relates to a stable oral instant montelukast film and its preparation method and application, wherein the film-forming material is a mixture of sodium hydroxypropyl methylcellulose and polyvinyl alcohol in a certain proportion . The product has high stability and is suitable for large-scale industrial production.

The invention discloses a Montelukast storage cabinet with functions of dust removing and drying. The Montelukast storage cabinet with the functions of dust removing and drying comprises a base, wherein universal wheels are fixed at all four corners of the outer wall of the bottom of the base through bolts, and a fan heater is fixed at one end of the inner wall of the bottom of the base through a bolt; the air outlet end of the fan heater is sleeved with an air outlet pipe, and an air outlet is formed in the outer wall of the top of the air outlet pipe; the inner wall of the air outlet is sleeved with an air outlet mouth, and a vacuum cleaner is fixed at the other end of the inner wall of the bottom of the base through a bolt; the air inlet of the vacuum cleaner is sleeved with a suction pipe, and an opening is formed in the outer wall of one side of the base. According to the Montelukast storage cabinet with the functions of dust removing and drying, the fan heater is controlled by adding a temperature humidity sensor and a controller, so that control over the humidity in the cabinet is facilitated, and a dry storage environment for Montelukast is ensured; the air in the cabinet can be purified by adding an air cleaner, so that the dry storage environment for Montelukast is ensured, and the storage cabinet has the functions of dust removing and drying, and is suitable for storing Montelukast.